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Abstract 
Purpose: Metastatic castration-resistant prostate cancer (mCRPC) is a heterogeneous disease 
for which better prognostic models for survival are needed. We examined the added value of 
circulating tumor cell (CTC) enumeration relative to common prognostic laboratory measures 
from CRPC patients. 
Experimental Technique:  Utility of CTC enumeration as a baseline and postbaseline 
prognostic biomarker was examined using data from two prospective randomized registration-
directed trials (COU-AA-301 and ELM-PC4) within statistical models used to estimate risk for 
survival. Discrimination and calibration were used to measure model predictive accuracy and 
the added value for CTC enumeration in the context of a Cox model containing albumin, lactate 
dehydrogenase (LDH), prostate-specific antigen (PSA), hemoglobin, and alkaline phosphatase 
(ALK). Discrimination quantifies how accurately a risk model predicts short-term versus long-
term survivors. Calibration measures the closeness of actual survival time to the predicted 
survival time. 
Results: Adding CTC enumeration to a model containing albumin, LDH, PSA, hemoglobin, and 
ALK (“ALPHA”) improved its discriminatory power. The weighted c-index for ALPHA without 
CTCs was 0.72 (SE, 0.02) versus 0.75 (SE, 0.02) for ALPHA + CTCs. The increase in 
discrimination was restricted to the lower-risk cohort. In terms of calibration, adding CTCs 
produced a more accurate model-based prediction of patient survival. The absolute prediction 
error for ALPHA was 3.95 (SE, 0.28) versus 3.75 months (SE, 0.22) for ALPHA + CTCs. 
Data Interpretation: Addition of CTC enumeration to standard measures provides more 
accurate assessment of patient risk in terms of baseline and postbaseline prognosis in the 
mCRPC population. 
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Introduction 
Studies in multiple tumor types have shown that circulating tumor cell (CTC) number measured 
with the CellSearch® assay is prognostic for survival before and after therapy (1-3). In 2004, the 
test received clearance from the US Food and Drug Administration as “an aid in the monitoring 
of patients with metastatic breast cancer” (4) and expanded to colorectal and prostate cancer in 
2007 (5) and 2008 (6), respectively. Use in practice has been limited, in part because of 
variations in reimbursement by third party payers, the costs including the devices and reagents 
needed to perform and the technical personnel to run it, and uncertainties in how to use the test 
result in patient management. The central question is whether the use of the CTC enumeration 
result provides incremental information that improves the ability to assess the prognosis of the 
patient relative to an assessment without the result. If the prognosis of survival time 
incorporating CTC enumeration meaningfully impacts patient management, its diagnostic utility 
will be clear. 
 
The conventional approach to determining whether a new biomarker adds value to current 
models is to establish its association with survival when combined with other known prognostic 
factors. The association analysis is often developed through a proportional hazards model, 
using the hazard ratio and P value affiliated with the new marker to establish its clinical 
importance.  These association analyses alone, however, are not sufficient to assess the 
magnitude of the added value of a biomarker. Here, we go beyond the standard association 
analyses by assessing whether CTC enumeration before and after treatment improves risk 
classification and the prediction of survival time for patients with metastatic castration-resistant 
prostate cancer (mCRPC). To do so, we compared models that contained and excluded CTCs 
for their ability to discriminate and calibrate survival times.  
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The analysis was performed using data from patients enrolled in the phase III registration trial of 
abiraterone acetate plus prednisone (COU-AA-301; NCT00638690) (7, 8) and independently 
validated using the data from patients in a second registration trial of similar design evaluating 
orteronel plus prednisone (ELM-PC4; NCT01193244) (9). The analysis included patients from 
both the treatment and control arms of these studies with the purpose of determining whether 
the predictive accuracy of the baseline and postbaseline CTC biomarker was agnostic to 
treatment.  Also noteworthy is that the COU-AA-301 trial population was docetaxel refractory 
and the ELM-PC4 population was chemotherapy naïve (7-9), which enabled the examination of 
the CTC signal in multiple mCRPC populations 
 
Methods 
Study design and participants. A proportional hazards model for survival was developed 
using baseline and posttreatment data from patients enrolled in the completed phase III 
registration trials of abiraterone acetate plus prednisone (COU-AA-301) and orteronel plus 
prednisone (ELM-PC4). The results of the trials have been reported previously (7-9). The 
biomarkers used for clinical prognostication were albumin, lactate dehydrogenase (LDH), 
prostate-specific antigen (PSA), hemoglobin, and alkaline phosphatase (ALK), which have 
previously been shown to be prognostic for survival in multivariate analysis and are components 
of several prediction models (nomograms) that estimate survival times in men with mCRPC (10-
14). The baseline values of albumin, LDH, PSA, hemoglobin, and ALK, along with the increase 
or decrease in PSA at week 13 relative to baseline, represent our submodel (called “ALPHA” in 
this article). For the ELM-PC4 analysis, a weighted proportional hazards model was used to 
account for the nonproportionality in the model. The weights enable the interpretation of the 
model coefficients as the average hazard ratio over time. All analyses were based on a 
landmark time of 12 weeks. 
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The objective of this study was to determine the incremental information provided by early post-
treatment  CTC measures in predicting patient survival. For each patient, a risk score was 
computed from both the ALPHA model and the model developed by adding baseline CTC 
enumeration and the increase or decrease in CTCs at week 13 relative to baseline. This model 
is referred to as ALPHA + CTC. Adding CTCs to the submodel indicates that both the baseline 
CTC values and the relative change in CTCs were included. For the CTC and PSA markers, the 
relative change was defined as: 
݉ܽݎ݇݁ݎ ݒ݈ܽݑ݁ ܽݐ ݓ݁݁݇ 13 − ݉ܽݎ݇݁ݎ ݒ݈ܽݑ݁ ܽݐ ܾܽݏ݈݁݅݊݁
݉ܽݎ݇݁ݎ ݒ݈ܽݑ݁ ܽݐ ܾܽݏ݈݁݅݊݁  
Because patients may not have detectable CTCs at baseline, CTC baseline values equal to 0 
were recorded as 1 for the CTC relative change variable.  The risk score for each patient is a 
weighted sum of his biomarkers in the proportional hazards model, where the weights are the 
regression coefficients derived from the model. 
 
Statistical analysis methods. Discrimination represents the model’s strength in differentiating 
long-term survivors from short-term survivors. It is illustrated graphically using negative and 
positive predictive value statistics (15). The negative predictive value is depicted with a Kaplan-
Meier curve estimating the probability of survival using the cohort of patients with low-risk 
scores derived from the proportional hazards models. The positive predictive value is defined as 
the probability of dying (one minus Kaplan-Meier) for patients with model-based high-risk 
scores. For the current analysis, the negative predictive value is computed using patients with 
the lowest 25% of the risk scores (presumed best prognosis), and the positive predictive value 
is calculated using patients with the highest 25% of the risk scores (presumed worst prognosis). 
To assess the added value of CTC enumeration, the negative and positive predictive values 
were computed for both models. An enhanced negative predictive value with CTCs would be 
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indicated by a Kaplan-Meier survival curve that is above the survival curve derived from the 
model developed without the CTC marker, while an improvement in the positive predictive value 
is represented by a higher one minus Kaplan-Meier curve for the model that included CTCs.  
 
In addition to a graphical analysis, the weighted concordance index (c-index) was computed to 
summarize the discriminatory power of each model to evaluate the added value of CTCs (16). 
The concordance index is the proportion of all pairs of patients, where the patient with a longer 
survival time also has a smaller risk score. The weighted c-index ranges between 0.5 and 1.0, 
where the value 0.5 indicates that the model cannot discriminate between long-term survivors 
and short-term survivors and a value of 1.0 indicates perfect discrimination.  A 10-fold cross-
validation procedure was used to compute the weighted c-indices and bootstrap 95% 
confidence intervals were computed for the associated parameter.  
 
A calibration metric is used to compare the model-based predicted survival time with the actual 
survival time of a patient (17). To gauge calibration for each model, the relationship between the 
observed time to death (for patients who died) and the median predicted survival time is illustrated 
graphically. Perfect calibration is represented by a 45° line through the origin showing that the 
observed times and the predicted median survival times were equal for all patients.  
 
A summary measure of calibration, termed the absolute prediction error (APE), is computed 
(18). The APE computes a weighted difference between the actual survival time and a predicted 
median survival time (19). The patient’s predicted survival time is computed from his model-
based risk score. An APE equal to zero indicates that the model-based predicted median 
survival is exactly equal to the true survival for all patients, which equates to the data lining up in 
a 45° line in the calibration plot described above. As the disparity between the observed and 
predicted survival increases, the APE increases.  
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Graphs and summary statistics of discrimination and calibration were computed. We evaluated 
the added value of CTC enumeration as a clinical predictor of survival. The results were 
validated using a patient cohort from the independent randomized clinical ELM-PC4 trial, which 
was designed to test the efficacy of orteronel plus prednisone in men with mCRPC. 
 
Results 
The randomized clinical trial comparing abiraterone acetate plus prednisone versus prednisone 
alone for patients with mCRPC enrolled 1195 patients. Of these, 949 had all baseline markers 
drawn and 648 patients were alive with CTC and PSA markers recorded at week 13 and were 
eligible for the landmark analysis. In addition, four patients had data values with extreme 
leverage points that had an overly influential effect on the analysis. One patient had a PSA 
relative change (from baseline to week 13) approximately equal to 100, two patients had CTC 
relative changes equal to 99, and the final patient had a CTC relative change approximately 
equal to 23. With these additional four patients excluded, data from 644 patients were used in 
the analysis (CONSORT diagram, Fig. 1A). The median survival time for the 644 patients under 
study was 16.8 months (95% CI, 15.6–18.0). A summary of the marker values for these 644 
patients is provided in Table 1. 
 
Table 2 provides a summary of the log relative risk coefficients from the proportional hazards 
model and their attendant standard errors and P values. In addition to the significance of many 
of the factors, the baseline and relative change in CTC enumeration demonstrated a strong 
association with survival time. However, association alone is not a sufficient measure of the 
prognostic utility of individual markers. 
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We examined the weighted c-index to numerically evaluate the value of adding CTCs to the 
model in terms of discrimination. The discriminatory power of ALPHA + CTC was 0.75 (SE, 
0.02). The weighted c-index for the model containing ALPHA (without CTCs) was 0.72 (SE, 
0.02)  (Table 3). A 95% bootstrap confidence interval for the difference in these two measures, 
indicating the magnitude of the improvement in discrimination due to the addition of CTCs, is  
(0.02, 0.05)  
 
A deeper analysis, presented visually, demonstrated where CTC enumeration provides added 
value as a prognostic marker of survival. A visual assessment of the improvement in 
discrimination, based on the addition of CTC, was obtained by graphing the negative and 
positive predictive values. For the negative predictive value (Fig. 2A), patients with low risk 
scores are expected to have prolonged survival times relative to the entire cohort. This 
improvement in survival is magnified in the model that includes CTCs. For the positive predictive 
value, which reflects patients with the poorest prognosis, there is no benefit to adding CTCs to 
the prognostic model (Fig. 2B). Thus, in terms of discrimination, the prognostic utility of CTC 
enumeration is manifested in the lower-risk cohort; the existing markers are sufficient for 
prognosis with the high-risk cohort. 
 
Taken together, the graphical and numerical discrimination analyses show that the addition of 
CTC enumeration improves the discriminatory power of the risk model relative to standard 
prognostic factors in this patient population and that the discrimination benefit is found in the 
lower-risk cohort.  
 
Calibration measures the closeness of the actual survival time to the model-based predicted 
survival. The APE is recorded to summarize the distance between the observed survival times 
and predicted median survival times. The APE for ALPHA + CTC is 3.75 months (SE, 0.22). 
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Removing CTCs from this model (ALPHA) increases the APE to 3.95 (SE, 0.28). Therefore, 
using APE, the inclusion of CTCs to the model provides a modest improvement in the accuracy 
of the predicted survival time (Table 3). The reduction in the APE due to CTC is 0.20 and the 
95% confidence for this difference is (-0.02, 0.51). 
 
The graphical calibration analysis compared the estimated median survival times to the 
observed survival times using smoothed curves for an uncluttered visual of this relationship (Fig. 
2c). The frequencies for the observed survival times are illustrated by the vertical lines at the 
bottom of the plot. As shown, the calibration curve for ALPHA + CTC is closer to the 45° line 
early in the follow-up period, but there remains significant distance between this curve and exact 
calibration in the early time period.  
 
Data from 908 patients enrolled on the ELM-PC4 study were used to validate the discrimination 
and calibration analyses (Fig. 1B, Table 2). In this patient population, the discrimination metric 
for ALPHA + CTC produced a weighted c-index of 0.75 (SE, 0.01). When removing CTCs from 
the model, the weighted c-index decreased to 0.71 (SE, 0.01) (Table 3). A 95% confidence for 
the difference in the two measures is (0.02, 0.64). A similar pattern occurred with the calibration 
metric. The APE for ALPHA + CTC was 3.56 months (SE, 0.24) and increased to 3.83 months 
(SE, 0.22) when CTCs were omitted from the model. The 95% confidence for this difference is 
(0.02, 0.66). The negative (Fig. 3A) and positive (Fig. 3B) predictive value curves and the 
calibration curves (Fig. 3C) produce parallel information to these summary measures. These 
results validate the discrimination and calibration analyses obtained from the COU-AA-301 set.  
 
Discussion 
Understanding the clinical importance of a post-therapy measure to assess long-term trial 
endpoints is an essential step in establishing outcome measures as indicators of clinical benefit 
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that can be used to support drug approval. To do so requires a determination of the prognosis of 
the patient cohort using risk factors measured at baseline and postbaseline.  The present study 
shows that the incorporation of the CTC number at baseline and the relative change in CTC 
number from baseline to week 13 provides an improvement in the predictive accuracy of a 
prognostic model for low-risk patients with respect to survival time. The results were validated 
using patient data from a comparable mCRPC trial, but with chemotherapy-naïve patients, in 
contrast to the initial study based on patients with prior docetaxel treatment.  
The discrimination analysis in the COU-AA-301 marker data demonstrated that, for defining a 
low-risk cohort, the addition of CTC number to the risk model produced higher survival rates 
relative to a risk model developed without CTC enumeration. Thus, the addition of CTC 
enumeration to the submodel improved the negative predictive value of the risk classification 
model. The finding was validated using an independent cohort of patients treated in the ELM-
PC4 trial, where the addition to CTCs to the submodel showed even greater separation in the 
survival curves among the low-risk cohort developed with and without CTCs.  
The calibration analysis established that the CTC-based model provided only a modest 
improvement in predicting survival time. Neither curve approaches the 45° line of equivalence 
between the model and actual survival time. There are two components that impact the 
accuracy of a calibration analysis. First, point prediction of survival time is complicated by many 
factors not related to disease, such as age or comorbidities. Second, there are disease-related 
factors, such as number of bone metastases, performance status, and Brief Pain Inventory-
Short Form score, to name a few, that are not included in the model. In our analysis, this is 
evident by the calibration curves in Fig. 3: the prediction of early deaths is poor, as shown by 
the distance or separation from the 45° line. 
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Complete biomarker data was not available for all patients. For patients who are alive at 13 
weeks and missing either the week 13 CTC or PSA recording, the data are not missing data at 
random. For the COU-AA-301 study, the median survival time for these patients is 13.4 months 
compared to a median survival time of 16.8 for the analysis cohort. However, the potential 
biases in the discrimination or calibration comparisons should approximately cancel because 
the same patient cohort was used for both risk models (ALPHA and ALPHA+CTC).   
The use of biomarkers during follow-up to accurately determine prognosis is essential for 
disease management. To this end, serial biologic profiling of the disease before treatment, 
during treatment, and at progression, and determining the association of the profiles with later 
events such as radiographic progression-free survival and/or overall survival, was included in 
the updated recommendations from the Prostate Cancer Clinical Trials Working Group 3 (20).  If 
applied early in the posttreatment period, the biomarker results may be useful for informing the 
decision to continue treatment if the patient-specific risk score is favorable or to discontinue 
treatment if the computed risk score is not.  
In this study, we found that CTC enumeration measured at baseline and early in the treatment 
phase, regardless of treatment received, provided incremental value to the clinical factors and 
laboratory test results acquired in the course of routine clinical practice. A limitation of the CTC 
CellSearch assay is that it only defines one circulating tumor cell type.  Whether non-selection 
based assays that enable the identification and enumeration of multiple cell types is more 
informative is unknown.  At this point, however, the results support a role for postbaseline CTC–
containing biomarkers as an indicator of prognosis. More research is needed to go beyond its 
prognostic utility and examine its clinical utility as an intermediate response variable.  
 
Translational Relevance 
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Previous studies in multiple tumor types have shown that pre- and posttreatment circulating 
tumor cell (CTC) number measured with the CellSearch® assay is prognostic for survival. Use of 
CTC enumeration in practice has been limited, in part due to costs, variations in reimbursement 
by third-party payers, and questions about the prognostic utility. In this study, we explored in 
greater depth the magnitude of the added value of CTCs in terms of its predictive accuracy for 
survival time. We found that CTC enumeration measured at baseline and early in the treatment 
phase provided incremental value in predictive accuracy relative to known biomarkers acquired 
in the course of routine clinical practice. These findings and those in previous studies suggest a 
role for posttreatment CTC–containing biomarkers as an indicator of patient risk.  
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Table 1. Summary of biomarker measures. 
 
Abbreviations: ALK, alkaline phosphatase; CTC, circulating tumor cells; LDH, lactate 
dehydrogenase; PSA, prostate-specific antigen. 
 
  
 COU-AA-301 study (N = 644) ELM-PC4 study (N = 908) 
Marker Median (Range) Median (Range) 
Baseline albumin 4.1 (2.9–4.9) 4.4 (2.5–5.4) 
Baseline ALK 114.5 (33–4617) 96.0 (35–3,281) 
Baseline CTC 4.0 (0–100) 2.0 (0–5,153) 
Baseline hemoglobin 12.0 (7.3–16.5) 12.9 (4.7–17.5) 
Baseline LDH 215.0 (84–3,373) 186.0 (67–1,868) 
Baseline PSA 119.2 (0.4–10,110) 49.7 (1.7–3,906) 
Week 13 CTC 1.0 (0–100) 0 (0–1,635) 
Week 13 PSA 97.5 (0.1–8,582) 31.6 (0–7682) 
Age 70 (42–95) 71 (49–89) 
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Table 2. Summary of association analysis in the COU-AA-301 and ELM-PC4a 
proportional hazards analysis.  
Factor Coefficient SE (coefficient) P value 
COU-AA-301    
Baseline albumin ‒0.678 0.171 <0.001 
Baseline log (ALK) ‒0.031 0.076 0.681  
Baseline log (CTC) 0.253 0.043 <0.001 
Baseline haemoglobin ‒0.008 0.041 0.842 
Baseline log (LDH) 1.161 0.135 <0.001 
Baseline log (PSA) 0.050 0.037 0.173 
Relative change in CTC 0.098 0.014 <0.001 
Relative change in PSA 0.222 0.029 <0.001 
ELM-PC4    
Baseline albumin ‒0.037 0.021 0.084 
Baseline log (ALK) 0.200 0.105 0.056  
Baseline log (CTC) 0.327 0.044 <0.001 
Baseline hemoglobin ‒0.013 0.005  0.007 
Baseline log (LDH) 0.047 0.175 0.787 
Baseline log (PSA) 0.067 0.047 0.153 
Relative change in CTC 0.089 0.026 <0.001 
Relative change in PSA 0.292 0.053 <0.001 
Abbreviations: ALK, alkaline phosphatase; CTC, circulating tumor cells; LDH, lactate 
dehydrogenase; PSA, prostate-specific antigen. 
aA weighted proportional hazards model was used to account for the nonproportionality in the 
ELM-PC4 risk model. 
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Table 3. Predictive accuracy summary measures from the COU-AA-301 and ELM-PC4 studies. 
 
 Weighted c-index APE 
 COU-AA-301 ELM-PC4 COU-AA-301 ELM-PC4 
ALPHA 0.72 0.71 3.95 3.83 
ALPHA + CTC 0.75 0.75 3.75 3.56 
Abbreviations: APE, absolute prediction error; ALPHA, alubmin, lactate dehydrogenase, 
prostate-specific antigen, hemoglobin, and alkaline phosphatase; CTC, circulating tumor cells. 
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Figure Legends 
Figure 1. Consort diagrams for the COU-AA-301 (A) and ELM-PC4 (B) studies. 
Figure 2. COU-AA-301 negative (A) and positive (B) predictive value and calibration (C) curves. 
Note: Negative predictive value includes patients in the lowest quartile and positive predictive 
value those in the highest of risk scores within each model. An improvement in the negative 
predictive value among these low-risk patients would be shown by an increase in the Kaplan-
Meier estimate. An improvement in the positive predictive value among these high-risk patients 
would be demonstrated by an increase in the one minus Kaplan-Meier estimate. Calibration 
represents the relationship between observed survival time and the median predicted survival 
time. A model with good calibration would closely approximate the 45° line through the origin. 
Figure 3. ELM-PC4 negative (A) and positive (B) predictive value and calibration (c) curves. 
Note: Negative predictive value includes patients in the lowest quartile of risk scores within each 
model; positive predictive value includes patients in the highest quartile of risk scores within 
each model; calibration represents the relationship between observed survival time and the 
median predicted survival time. 
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